Effect of SRT2104 on endotoxin-induced inflammation.
- Conditions
- Gram negative infection, Sepsis, Lipopolysaccharide, SRT21040, Sirtuins, innate immunity
- Registration Number
- NL-OMON21773
- Lead Sponsor
- Academic Medical Center (AMC), Center of Experimental Molecular Medicine
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 24
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
1. Healthy, as determined by a responsible and experienced physician, based on a
medical evaluation including medical history, physical examination and laboratory tests
carried out within 28 days prior to day 1. A subject with a clinical abnormality or
laboratory parameters outside the reference range for the population being studied may
be included only if the Investigator and the Medical Monitor agree that the finding is
unlikely to introduce additional risk factors and will not interfere with the study
procedures;
1. Known diseases;
2. A history of smoking within the last six months, or regular consumption of greater than three units of alcohol per day;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary study endpoints include clinical signs and symptoms and laboratory parameters for inflammation (cytokines, activation of leukocytes, coagulation and vascular endothelium).
- Secondary Outcome Measures
Name Time Method Secondary endpoints include pharmacokinetics and safety recordings. Exploratory endpoints include lipid profiles, acute phase proteins, metabolic profiles and gene expression analysis from white blood cells. <br>